Electronic toxicity monitoring and patient-reported outcomes

Cancer Journal

Volumn 17, Issue 4, 2011, Pages 231-234

  Basch, Ethan M ^a   Reeve, Bryce B ^b   Mitchell, Sandra A ^c   Clauser, Stephen B ^c   Minasian, Lori ^c   Sit, Laura ^a   Chilukuri, Ram ^d   Baumgartner, Paul ^d   Rogak, Lauren ^a   Blauel, Emily ^a   Abernethy, Amy P ^e   Bruner, Deborah ^f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SemanticBits LLC   (United States)

^e DUKE CANCER INSTITUTE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adverse event; CTCAE; patient reported outcome; PRO; PRO CTCAE; symptom; tolerability; toxicity

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVERSE DRUG REACTION; ASTHMA; BREAST CANCER; CANCER THERAPY; COMPUTER INTERFACE; COMPUTER PROGRAM; DISEASE SEVERITY; DRUG INFORMATION; DRUG LABELING; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; GASTROESOPHAGEAL REFLUX; HEALTH STATUS; HUMAN; HYPERLIPIDEMIA; INFORMATION PROCESSING; MEDICAL INFORMATICS; NATIONAL HEALTH ORGANIZATION; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PATIENT MONITORING; PATIENT SAFETY; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SELF REPORT; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; COMPUTER COMMUNICATION NETWORKS; DRUG MONITORING; HUMANS; NEOPLASMS; RESEARCH REPORT; SOFTWARE; TREATMENT OUTCOME;

EID: 80051715635     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31822c28b3     Document Type: Review

References (16)

1. Institute of Medicine, National Academy of Sciences. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: National Academies Press; 2006.
2. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362:865-869.
3. Edgerly M, Fojo T. Is there room for improvement in adverse event reporting in the era of targeted therapies? J Natl Cancer Inst. 2008;100:240-242. (Pubitemid 351480535)
4. Duke J, et al. A quantitative analysis of adverse events and 'overwarning' in drug labeling. Arch Intern Med. 2011;171:944-946.
5. Trotti A, Colevas AD, Setser A, et al. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007;25:5121-5127. (Pubitemid 350232293)
6. Pakhomov SV, Jacobsen SJ, Chute CG, et al. Agreement between patientreported symptoms and their documentation in the medical record. Am J Manag Care. 2008;14:530-539.
7. Fromme EK, Eilers KM, Mori M, et al. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patientreported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004;22:3485-3490. (Pubitemid 41103654)
8. U. S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Patient-Reported Outcomes Measures: Use in Medical Product Development to Support Labeling Claims, December 2009. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed June 30, 2011.
9. Lipscomb J, Reeve BB, Clauser SB, et al. Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol. 2007;25:5133-5140. (Pubitemid 350232295)
10. Basch E, Jia X, Heller G, et al. Adverse symptom reporting by patients versus clinicians: relationships with clinical outcomes. J Nat Cancer Inst. 2009;101:1-9.
11. Meacham R, McEngart D, O'Gorman H, et al. Use and compliance with electronic patient reported outcomes within clinical drug trials. Presented at the 2008 ISPOR (International Society for Pharmacoeconomics and Outcomes Research) Annual International Meeting May 5, 2008; Toronto, Ontario, Canada.
12. National Cancer Institute. PRO-CTCAE Wiki Website, Item Development Literature Search Results Page. Available at: https://wiki.nci.nih.gov/x/TBGy. Accessed June 30, 2011.
13. Hay J, Atkinson TM, Mendoza TR, et al. Refinement of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) via cognitive interviewing. Presented at the 2010 ASCO Annual Meeting, Chicago, IL. J Clin Oncol. 2010;28:15s. Suppl; Abstract 9060.
14. Dueck AC, Mendoza TR, Reeve BB, et al. Validation study of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Presented at the 2010 ASCO Annual Meeting, Chicago, IL. J Clin Oncol. 2010;28:15 s. Suppl; Abstract TPS274.
15. Agarwal H, Gulati M, Baumgartner P, et al. Web Interface for the Patient-Reported Version of the CTCAE. NCI caBIG Annual Meeting; July 2009; Washington, DC.
16. Basch E, Abernethy AP. Supporting clinical practice decisions with realtime patient-reported outcomes. J Clin Oncol. 2011;29:954-956.